Moberg Pharma AB (MOB) Fair Value & Analysis
Healthcare · SE · Market cap 468M SEK
Fair value as of: Jul 17, 2026
From 3 valuation models · updated today
Share price −4.9% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 7.79 – kr 12.40 · fair‑value band kr 5.05 – kr 14.15 · the kr 9.35 price screens below the kr 9.70 fair value. As of Jul 17, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Moberg Pharma AB (MOB) currently trades at kr 9.35, while our model-based Fair Value estimate is kr 9.70, implying the stock looks roughly 3.8% fairly valued today. We read business quality at 31/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Revenue grew 101.4% year over year. It earns a return on equity of -4.0%. The balance sheet holds a net cash position of 228M SEK. Fundamentals as of Jul 17, 2026
Our scenario range runs from kr 5.05 (bear case) to kr 14.15 (bull case); at kr 9.35, the current price sits within that range. The share trades about 34% below its 52-week high and 24% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -44% fair-value upside, at 4%, MOB screens cheaper than that median.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 17, 2026. TTM = trailing twelve months.
About the company
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Moberg Pharma AB reported revenue of kr 13.5M in FY2025 versus kr 210M in FY2021, a compound −49.6%/yr. Reported net income was −kr 27.2M in FY2025.
Is MOB fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| PharmaEssentia Corporation 6446 | 937.00 TWD | 322.35 TWD | -66% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,401 | ₹592.37 | -58% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,291 | ₹1,053 | -18% |
| Lupin Limited LUPIN | ₹2,340 | ₹2,477 | +6% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Moberg Pharma AB (MOB) undervalued?
What is the fair value of MOB?
What is the quality score of MOB?
What is the net profit margin of MOB?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Tell me when Moberg Pharma AB reaches its Fair Value
Just your email, and we'll notify you when the price and Fair Value of Moberg Pharma AB materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.